Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals Ltd has launched AlgoraeOS Version 2, a significant upgrade to its AI platform for drug-combination discovery. This new version outperforms state-of-the-art models, providing more reliable predictions for drug synergy, which is expected to enhance the company’s preclinical development pipeline. By integrating biological knowledge with uncertainty-aware deep learning, AlgoraeOS v2 offers a decision-grade tool for prioritizing drug combinations and designing preclinical studies, thus reinforcing Algorae’s leadership in AI-driven therapeutic discovery.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on AI-enabled drug discovery. The company specializes in developing advanced AI platforms for drug-combination discovery, with a market focus on enhancing therapeutic discovery and preclinical development pipelines.
Average Trading Volume: 2,838,828
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$15.19M
For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.